Clinical Trial: A Single‑arm, Single‑center, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined with Anlotinib in the Treatment of Second‑line and Above Recurrent or Metastatic SMARCA4‑deficient Non‑small Cell Lung Cancer (China)

China, Sept. 7 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Single‑arm, Single‑center, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined with Anlotinib in the Treatment of Second‑line and Above Recurrent or Metastatic SMARCA4‑deficient Non‑small Cell Lung Cancer'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131693

Registration Time: 2026/09/05

Type: Interventional study

Primary Sponsor: Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=339576

Published by HT Digital Content Servi...